Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of November 2024. The report details a material event involving Evogene's subsidiary, Lavie Bio Ltd., and its collaboration with Corteva Agriscience LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial detail disclosed is that Lavie Bio received an initial payment from Corteva upon signing the terminated agreement, which will not be repaid.
Material Changes
- Agreement Termination: Corteva Agriscience LLC terminated the licensing agreement dated July 14, 2023, regarding bio-fungicide lead candidates.
- Reason for Termination: Corteva cited an internal review and strategic prioritization process, terminating the agreement without cause.
- Effective Date: The termination becomes effective 90 days from the receipt of the notice (November 27, 2024).
- Scope: All activities related to the licensed technology under this specific agreement are discontinued, though other collaboration programs between the parties continue as planned.
- Intellectual Property: Lavie Bio regains all rights to the licensed technology and lead bio-fungicide candidates.
Outlook, Management Commentary, and Risks
Lavie Bio intends to continue developing its bio-fungicide pipeline using its proprietary computational predictive biology platform and expertise in microbiome-based solutions. The filing notes that the initial payment received from Corteva is non-refundable, representing a retained financial benefit despite the termination. No specific risks or contingencies beyond the termination itself are detailed in this text.
Investor Verification Checklist
- Verify the exact amount of the non-refundable initial payment received from Corteva.
- Confirm the status and financial terms of the remaining collaboration programs between Lavie Bio and Corteva.
- Assess the impact of regaining rights to the bio-fungicide candidates on future development costs and timelines.
- Review the company's broader cash position to determine if the retained payment significantly alters liquidity.